Pharmafile Logo
Pharmafocus logo
Advanced Search

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

January 5, 2023
Business Services

Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …

News
Press release

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

January 5, 2023
Business Services

Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …

News
Press release

FDA accepts application for nirsevimab as first protective option for RSV in infants

January 5, 2023
Medical Communications

The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease …

News

Island Pharmaceuticals to begin phase 2 trial for dengue prevention and treatment drug

January 5, 2023
Research and Development

It is possible that Island Pharmaceuticals could begin its phase 2a PEACH clinical trial as soon as January 2023. The …

News

Belharra Therapeutics and Genentech join forces for small molecule medicine development

January 5, 2023
Research and Development

US-based biotech companies Belharra Therapeutics and Genentech have announced a multi-year partnership to lead the discovery and development of small …

News

Biogen and Alcyone Therapeutics enter partnership to develop ThecaFlex DRx system for ASO therapies

January 5, 2023
Research and Development

US-based Biogen and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System.   …

News

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

January 4, 2023
Business Services

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.

News
Press release

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

January 4, 2023
Business Services

Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …

News
Press release

Dr Samson Fung

January 4, 2023
Business Services

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing …

Appointment

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders

January 4, 2023
Business Services

London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …

News
Press release

FDA expands access to abortion pills

January 4, 2023
Medical Communications

Following new rules from the FDA under the Biden administration, patients can now obtain the abortion pill mifepristone from retail …

News

Novartis pays $245m to settle Exforge generic pay-for-delay lawsuit

January 4, 2023
Medical Communications

Swiss pharma company Novartis will settle a classic generic pay-for-delay legal battle with direct purchasers, indirect purchasers and retailers regarding …

News

FDA grants Breakthrough Device Designation for Burning Rock’s multi-cancer detecting test

January 4, 2023
Medical Communications

Burning Rock, a Chinese biotech company which focuses on the applications of next-generation sequencing (NGS) technology in the field of …

News

FDA expected to make decision on controversial Alzheimer’s drug this week

January 4, 2023
Medical Communications

The FDA are expected to come to a decision on Eisai and Biogen’s Alzheimer’s drug lecanemab by the end of …

News

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

January 3, 2023
Business Services

Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.

News
Press release

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

January 3, 2023
Business Services

BEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a …

News
Press release

Cost of over 350 drugs expected to increase in 2023

January 3, 2023
Sales and Marketing

With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation …

News

Rare cancer drug for young patients approved

January 3, 2023
Research and Development

A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA …

News

MediWound receives FDA approval for NexoBrid

January 3, 2023
Medical Communications

Israeli biopharma company MediWound has secured FDA approval for its wound care product NexoBrid (anacaulase-bcdb). US-based biopharma company Vericel will …

News

Datar blood test receives FDA Breakthrough Designation

January 3, 2023
Medical Communications

Datar Cancer Genetics has secured FDA Breakthrough Designation for their blood test used to detect inaccessible brain tumours, where traditional …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026